Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556931 | 1.00 | MEN1 (0.60) | MEN1KMT2ALMNAATML3MBTL1 | |
| Hydrochloric Acid SCHEMBL8620287 | 0.99 | MEN1 (0.59) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL6555294 | 0.99 | MEN1 (0.61) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL6555248 | 0.96 | MEN1 (0.61) | MEN1KMT2ALMNAATML3MBTL1 | |
| SCHEMBL6556892 | 0.94 | MEN1 (0.64) | MEN1KMT2AATML3MBTL1TACR1 | |
| Hydrochloric Acid SCHEMBL8621173 | 0.93 | MEN1 (0.63) | MEN1KMT2AATML3MBTL1TACR1 | |
| SCHEMBL6555183 | 0.87 | CYP2D6 (0.49) | MEN1KMT2ALMNAL3MBTL1TACR1 | |
| SCHEMBL6556838 | 0.86 | SGPL1 (0.48) | MEN1KMT2AL3MBTL1KDM1AMAOA | |
| SCHEMBL8620404 | 0.85 | CYP2D6 (0.50) | MEN1KMT2ALMNAL3MBTL1TACR1 | |
| SCHEMBL8620048 | 0.85 | SGPL1 (0.49) | MEN1KMT2AL3MBTL1BCHEKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0613458-B1 | ACYCLIC ETHYLENEDIAMINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS | PFIZER (US) | 1998-01-07 | — | — | EP | claimed |
| JP-2614408-B2 | — | — | 1997-05-28 | — | — | JP | claimed |
| US-5521220-A | Acyclic ethylenediamine derivatives | PFIZER INC. (US) | 1996-05-28 | — | — | US | claimed |
| EP-0613458-A1 | ACYCLIC ETHYLENEDIAMINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1994-09-07 | — | — | EP | claimed |
| WO-1993010073-A1 | ACYCLIC ETHYLENEDIAMINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0721778-B1 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6376507-B1 | NERVE SYSTEM DISORDERS, AMYOTROPIC LATERAL SCLEROSIS | PFIZER INC. | 2002-04-23 | — | — | US | disclosed |
| US-6177450-B1 | MIXTURE OF PERHYDROISOINDENE COMPOUND AND BENEZAMIDE COMPOUND | AVENTIS PHARMA S.A. | 2001-01-23 | — | — | US | disclosed |
| US-5750535-A | Pharmaceutical agents for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0613458-B1 | ACYCLIC ETHYLENEDIAMINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS | PFIZER (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0790825-A1 | NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EYE DISORDERS | PFIZER INC. (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0721778-A2 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER INC. (US) | 1996-07-17 | — | — | EP | disclosed |
| EP-0655246-A1 | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | disclosed |
| US-5393762-A | Pharmaceutical agents for treatment of emesis | PFIZER INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0627221-A2 | Substance P antagonists for the treatment of emesis | PFIZER INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0613458-A1 | ACYCLIC ETHYLENEDIAMINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1994-09-07 | — | — | EP | disclosed |
| US-5340826-A | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-23 | — | — | US | disclosed |
| EP-0610021-A1 | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993010073-A1 | ACYCLIC ETHYLENEDIAMINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1993-05-27 | — | — | WO | disclosed |